WO1998003178A3 - Pharmaceutical compositions containing p2y purinergic receptor antagonists - Google Patents

Pharmaceutical compositions containing p2y purinergic receptor antagonists Download PDF

Info

Publication number
WO1998003178A3
WO1998003178A3 PCT/EP1997/003844 EP9703844W WO9803178A3 WO 1998003178 A3 WO1998003178 A3 WO 1998003178A3 EP 9703844 W EP9703844 W EP 9703844W WO 9803178 A3 WO9803178 A3 WO 9803178A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
compositions containing
receptor antagonists
purinergic receptor
receptor
Prior art date
Application number
PCT/EP1997/003844
Other languages
French (fr)
Other versions
WO1998003178A2 (en
Inventor
Frank Brown
Davina Elizabeth Mitchell
Ariyan Tufiq Rahim
Brian Robert Stewart
Original Assignee
Smithkline Beecham Plc
Frank Brown
Davina Elizabeth Mitchell
Ariyan Tufiq Rahim
Brian Robert Stewart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Frank Brown, Davina Elizabeth Mitchell, Ariyan Tufiq Rahim, Brian Robert Stewart filed Critical Smithkline Beecham Plc
Publication of WO1998003178A2 publication Critical patent/WO1998003178A2/en
Publication of WO1998003178A3 publication Critical patent/WO1998003178A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The use of a P2Y receptor antogonist, in particular, a P2Y1 receptor antagonist, in the manufacture of a medicament for use in the treatment of CNS neurodegenerative disorders where an inflammatory component has been suggested (such as Alzheimer's disease) or peripheral demylinating diseases, such as Guillain Barre syndrome and central demylinating diseases, such as multiple sclerosis.
PCT/EP1997/003844 1996-07-19 1997-07-15 Pharmaceutical compositions containing p2y purinergic receptor antagonists WO1998003178A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9615202.0A GB9615202D0 (en) 1996-07-19 1996-07-19 Pharmaceuticals
GB9615202.0 1996-07-19

Publications (2)

Publication Number Publication Date
WO1998003178A2 WO1998003178A2 (en) 1998-01-29
WO1998003178A3 true WO1998003178A3 (en) 1998-03-19

Family

ID=10797198

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/003844 WO1998003178A2 (en) 1996-07-19 1997-07-15 Pharmaceutical compositions containing p2y purinergic receptor antagonists

Country Status (2)

Country Link
GB (1) GB9615202D0 (en)
WO (1) WO1998003178A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2325285T3 (en) 1998-12-01 2009-08-31 Phylonix Pharmaceuticals Inc. METHODS TO ENTER HETEROLOGICAL CELLS IN FISH.
IT1303815B1 (en) * 1998-12-02 2001-02-23 Consiglio Nazionale Ricerche USE OF SELECTIVE COMPOUND MODULATORS OF PURINIC RECEPTORS P2 FOR THE PREVENTION OF DAMAGES AND MORTALITY CAUSED BY ISCHEMIA
GB0120704D0 (en) * 2000-09-01 2001-10-17 Glaxo Group Ltd Polypeptide
DE10104825A1 (en) * 2001-02-01 2002-08-08 Florian Lang Antimalarial screening
JP4773951B2 (en) 2003-03-03 2011-09-14 エーザイ インコーポレーテッド Thiolactone
ES2223287B1 (en) * 2003-08-04 2006-04-16 Universidad Del Pais Vasco-Euskal Herriko Unibertsitatea COMPOUNDS FOR THE TREATMENT OF DEMIELINIZING AND AUTOIMMUNE DISEASES.
EP1674580A1 (en) * 2004-12-23 2006-06-28 F. Hoffmann-La Roche Ag Method for identifying activators and/or inhibitors of enzyme activity
CA2608504A1 (en) * 2005-05-31 2006-12-07 Duska Scientific Co. Inhibition of neuronal damage
EP1951262A4 (en) * 2005-11-21 2010-09-15 Univ Alabama Methods of using small molecule compounds for neuroprotection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035304A1 (en) * 1994-06-22 1995-12-28 Macronex, Inc. Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines
WO1997004760A1 (en) * 1995-07-28 1997-02-13 Consiglio Nazionale Delle Ricerche Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035304A1 (en) * 1994-06-22 1995-12-28 Macronex, Inc. Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines
WO1997004760A1 (en) * 1995-07-28 1997-02-13 Consiglio Nazionale Delle Ricerche Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ABBRACCHIO: "Modulation of astroglial cell proliferation by analogues of adenosine and ATP in primary cultures of rat striatum", NEUROSCIENCE, vol. 59, no. 1, 1994, pages 67 - 76, XP002048693 *
BITTON: "Phramacological variables associated with the development of neurologic toxicity in patients treated with suramin", J. CLIN. ONCOL., vol. 13, no. 9, 1995, pages 2223 - 2229, XP002048689 *
CICCARELLI: "Non-uniform effects mediated by P2Y receptors on the proliferation of cultured astrocytes", RES. COMM. MOL. PATHOL. PHARMACOL., vol. 87, no. 1, January 1995 (1995-01-01), pages 47 - 48, XP002048691 *
GILL: "Mechanism of suramin toxicity in stable myelinating dorsal root ganglion cultures", EXP. NEUROL., vol. 133, no. 2, 1995, pages 113 - 124, XP002048688 *
HARDEN T K ET AL: "P2-PURINERGIC RECEPTORS: SUBTYPE-ASSOCIATED SIGNALING RESPONSES AND STRUCTURE", ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, vol. 35, 1995, pages 541 - 579, XP000616487 *
MCGEER: "The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases", BRAIN RES. REV., vol. 21, 1995, pages 195 - 218, XP002048690 *
MOTIN L ET AL: "EFFECT OF P2-PURINOCEPTOR ANTAGONISTS ON GLUTAMATERGIC TRANSMISSION IN THE RAT HIPPOCAMPUS", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol. 115, no. 7, August 1995 (1995-08-01), pages 1276 - 1280, XP000610538 *
NOVALES-LI: "In-vitro immunopharmacologic effect of suramin on modifying Th-subset cytokine levels in splenocytes and T-cell clones: a therapeutic application for autoimmune disease", IMMUNOL. LETT., vol. 51, no. 3, 1996, pages 169 - 173, XP002048686 *
POLLACK S J ET AL: "SULFONATED DYES ATTENUATE THE TOXIC EFFECTS OF BETA-AMPLOID IN A STRUCTURE-SPECIFIC FASHOIN", NEUROSCIENCE LETTERS, vol. 197, 1995, pages 211 - 214, XP000612230 *
RATHBONE: "Adenosine and its nucleotides stimulate proliferation of chick astrocytes and human astrocytoma cells", NEUROSCI. RES., vol. 7, no. 1, February 1992 (1992-02-01), pages 1 - 17, XP002048692 *
SUN: "Action of extracellular calcium on suramin-induced inhibtion of neurite outgrowth of cultured rat dorsal root ganglia", J. NEUROCHEM., vol. 64, no. supp.1, 1995, pages s26, XP002048694 *
VOLONTE: "Selective P2 purinoceptor modulators prevent glutamate-evoked cytotoxicity in cultured cerebellar granule neurons", J. NEUROSCI. RES., vol. 45, no. 2, 15 July 1996 (1996-07-15), pages 183 - 193, XP002048687 *

Also Published As

Publication number Publication date
WO1998003178A2 (en) 1998-01-29
GB9615202D0 (en) 1996-09-04

Similar Documents

Publication Publication Date Title
WO2002080969A1 (en) Remedies for infant chronic arthritis-relating diseases
CA2392879A1 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
CA2366268A1 (en) Pharmaceutical compositions for cns and other disorders
IL179017A0 (en) Solid oral dosage form comprising valsartan
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
HUP9903906A3 (en) Use of chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
AU3846901A (en) Oral, nasal and pulmonary dosage formualtions of copolymer 1
NO306457B1 (en) 2,4-disulfonylphenylbutylnitron, salts thereof, pharmaceutical composition, and the use of this compound in the manufacture of a medicament
WO1995031985A3 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
CA2195425A1 (en) Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri
ZA964851B (en) Treatment of t cell mediated autoimmune disorders
IL112895A (en) Pharmaceutical compositions for the treatment of obsessive-compulsive disorders comprising 5-HT2 antagonists
HUP0302333A3 (en) The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
WO2002078745A3 (en) Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
WO1998003178A3 (en) Pharmaceutical compositions containing p2y purinergic receptor antagonists
AU8188691A (en) The use of inositoltrisphosphate for the preparing of medicaments
HUP9702244A3 (en) Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders
CA2166332A1 (en) Antiglucocorticoid steroids for the treatment of anxiety disorders
ATE375789T1 (en) ORAL DELIVERY SYSTEM CONTAINING AN ANTIBACTERIAL AND AN ANTI-INFLAMMATORY AGENT
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
CA2132544A1 (en) Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
BG106548A (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
CA2217513A1 (en) Pharmaceutical agents for the treatment of alzheimer's disease
EE200100689A (en) Use of IL6RIL6 Chimera for the preparation of a medicament for the treatment of neurological diseases, and pharmaceutical composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 98506556

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase